Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization

Basit Öğe Kaydı
dc.contributor.authorIqbal, O
dc.contributor.authorTobu, M
dc.contributor.authorAziz, S
dc.contributor.authorGerdisch, M
dc.contributor.authorDa Valle, M
dc.contributor.authorDemir, M
dc.contributor.authorHoppensteadt, DA
dc.date.accessioned2024-06-12T11:17:35Z
dc.date.available2024-06-12T11:17:35Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractRefludan (lepirudin-rDNA for injection) is the first direct thrombin inhibitor approved by the United States FDA for anticoagulation to patients with heparin-induced thrombocytopenia (HIT). It was monitored by ecarin clotting time (ECT) assay in patients with HIT. Case histories and clotting parameters for three patients undergoing off-pump coronary artery revascularization procedure are discussed. The first patient received r-hirudin at a dose of 0.2 mg/kg intravenous (IV) bolus followed by 0.15 mg/kg/hour infusion. The second patient received 0.4 mg/kg IV bolus followed by infusion of 0.15 mg/kg/hour infusion. The third patient with renal failure received 0.2 mg/kg IV bolus followed by an infusion of 0.02 mg/kg/hour. Blood samples were drawn at baseline, 5 minutes post bolus and every 15 minutes during the coronary artery revascularization procedure. ECT was performed immediately on the citrated whole blood samples using the ECT cards in conjunction with the point-of-care, the thrombolytic assessment system (TAS) Analyzer (Pharmanetics, Raleigh, NC). The plasma samples were then analyzed for APTT and liquid ECT assay performed on a kinetic centrifugal analyzer (ACL 300 Plus). The ECT by cards was ideally maintained above 600 seconds during the surgical procedure. Additional boluses of Refludan were given as and when necessary (ECT < 600 sec) in order to maintain adequate anticoagulation. The calculated circulating concentrations of Refludan, following a bolus adminstration, based on the ECT cards, liquid ECT and APTT were 3.20 +/- 1.3, 3.51 +/- 1.35 and 2.02 +/- 1.19 mug/mL, respectively.en_US
dc.identifier.doi10.1111/j.0886-0440.2005.200316.x
dc.identifier.endpage51en_US
dc.identifier.issn0886-0440
dc.identifier.issue1en_US
dc.identifier.pmid15673409en_US
dc.identifier.scopus2-s2.0-19944432432en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage42en_US
dc.identifier.urihttps://doi.org/10.1111/j.0886-0440.2005.200316.x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24769
dc.identifier.volume20en_US
dc.identifier.wosWOS:000226958900007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBlackwell Futura Publishing, Incen_US
dc.relation.ispartofJournal Of Cardiac Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnticoagulanten_US
dc.subjectInhibitionen_US
dc.subjectVolunteersen_US
dc.subjectCgp-39393en_US
dc.subjectThrombinen_US
dc.subjectSafetyen_US
dc.titleSuccessful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularizationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu